{"id":"https://openalex.org/W4283324576","doi":"https://doi.org/10.1097/01.hs9.0000843768.58631.ac","title":"S219: FIRST CLINICAL STUDY OF THE ANTI-SIGNAL REGULATORY PROTEIN-ALPHA (SIRP\u0391) ANTIBODY CC-95251 COMBINED WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL)","display_name":"S219: FIRST CLINICAL STUDY OF THE ANTI-SIGNAL REGULATORY PROTEIN-ALPHA (SIRP\u0391) ANTIBODY CC-95251 COMBINED WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL)","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4283324576","doi":"https://doi.org/10.1097/01.hs9.0000843768.58631.ac"},"language":"en","primary_location":{"id":"doi:10.1097/01.hs9.0000843768.58631.ac","doi":"https://doi.org/10.1097/01.hs9.0000843768.58631.ac","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000843768.58631.ac","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1097/01.hs9.0000843768.58631.ac","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038196228","display_name":"Paolo Strati","orcid":"https://orcid.org/0000-0002-7445-1459","observed_orcids":["https://orcid.org/0000-0002-7445-1459"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"P. Strati","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, United States of America","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006324385","display_name":"Eliza Anne Hawkes","orcid":"https://orcid.org/0000-0002-0376-2559","observed_orcids":["https://orcid.org/0000-0002-0376-2559"]},"institutions":[{"id":"https://openalex.org/I2800453128","display_name":"Austin Hospital","ror":"https://ror.org/010mv7n52","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800453128","https://openalex.org/I4210163497"]},{"id":"https://openalex.org/I4210163497","display_name":"Austin Health","ror":"https://ror.org/05dbj6g52","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210163497"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"E. Hawkes","raw_affiliation_strings":["Austin Health\u2013Austin Hospital, Heidelberg, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Austin Health\u2013Austin Hospital, Heidelberg, Australia","institution_ids":["https://openalex.org/I2800453128","https://openalex.org/I4210163497"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074766331","display_name":"Nilanjan Ghosh","orcid":"https://orcid.org/0000-0002-3848-6136","observed_orcids":["https://orcid.org/0000-0002-3848-6136","https://orcid.org/0000-0002-7217-243X"]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. Ghosh","raw_affiliation_strings":["Levine Cancer Institute, Charlotte"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Levine Cancer Institute, Charlotte","institution_ids":["https://openalex.org/I4210100342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044602269","display_name":"Joe Tuscano","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I84218800","display_name":"University of California, Davis","ror":"https://ror.org/05rrcem69","country_code":"US","type":"education","lineage":["https://openalex.org/I84218800"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Tuscano","raw_affiliation_strings":["University of California, Davis, Sacramento, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, Davis, Sacramento, United States of America","institution_ids":["https://openalex.org/I84218800"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008742208","display_name":"Q. Chu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405258411","display_name":"Cross Cancer Institute","ror":"https://ror.org/00m3k3802","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I4405258411"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Q. Chu","raw_affiliation_strings":["Cross Cancer Institute, Edmonton, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cross Cancer Institute, Edmonton, Canada","institution_ids":["https://openalex.org/I4405258411"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090348753","display_name":"Mary Ann Anderson","orcid":"https://orcid.org/0000-0002-3515-0215","observed_orcids":["https://orcid.org/0000-0002-3515-0215"]},"institutions":[{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"M. A. Anderson","raw_affiliation_strings":["Peter MacCallum Cancer Centre, Melbourne, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Peter MacCallum Cancer Centre, Melbourne, Australia","institution_ids":["https://openalex.org/I2800555584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085487452","display_name":"Ahsan Shoeb Patel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Patel","raw_affiliation_strings":["Bristol Myers Squibb, Princeton"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041168751","display_name":"M. R. Burgess","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. R. Burgess","raw_affiliation_strings":["Bristol Myers Squibb, Princeton"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052566719","display_name":"K. Hege","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Hege","raw_affiliation_strings":["Bristol Myers Squibb, Princeton"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009281809","display_name":"Sapna Chhagan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Chhagan","raw_affiliation_strings":["Bristol Myers Squibb, Princeton"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020825071","display_name":"S. Boyanapalli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Boyanapalli","raw_affiliation_strings":["Bristol Myers Squibb, Princeton"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039108447","display_name":"Travis W. Day","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T. Day","raw_affiliation_strings":["Bristol Myers Squibb, Princeton"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034872191","display_name":"F. Shen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. Shen","raw_affiliation_strings":["Bristol Myers Squibb, Princeton"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030631799","display_name":"Amitkumar Mehta","orcid":"https://orcid.org/0000-0003-0537-4207","observed_orcids":["https://orcid.org/0000-0003-0537-4207"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Mehta","raw_affiliation_strings":["University of Alabama at Birmingham, Birmingham, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Birmingham, United States of America","institution_ids":["https://openalex.org/I32389192"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5038196228"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":2480,"currency":"USD","value_usd":2480},"apc_paid":{"value":2480,"currency":"USD","value_usd":2480},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0597417,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"6","issue":null,"first_page":"120","last_page":"121"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12672","display_name":"Phagocytosis and Immune Regulation","score":0.9092000126838684,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12672","display_name":"Phagocytosis and Immune Regulation","score":0.9092000126838684,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.07129999995231628,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.006300000008195639,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sirpalpha","display_name":"SIRP\u03b1","score":0.8970000147819519},{"id":"https://openalex.org/keywords/cd47","display_name":"CD47","score":0.7789999842643738},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9670000076293945},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.8880000114440918},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.972000002861023},{"id":"https://openalex.org/keywords/phagocytosis","display_name":"phagocytosis","score":0.7730000019073486},{"id":"https://openalex.org/keywords/macrophages","display_name":"macrophages","score":0.6650000214576721},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.7369999885559082},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.3630000054836273},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.828000009059906},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.859000027179718},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6729999780654907},{"id":"https://openalex.org/keywords/cd20-positive-lymphoma","display_name":"CD20-positive lymphoma","score":0.7289999723434448},{"id":"https://openalex.org/keywords/on-target-off-tumor-toxicity","display_name":"on-target off-tumor toxicity","score":0.7590000033378601}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7237166166305542},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.5431962609291077},{"id":"https://openalex.org/C2780104668","wikidata":"https://www.wikidata.org/wiki/Q21108354","display_name":"CD47","level":3,"score":0.4927411377429962},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.47419339418411255},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4603556990623474},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4555252492427826},{"id":"https://openalex.org/C2776146153","wikidata":"https://www.wikidata.org/wiki/Q7281276","display_name":"Radioimmunotherapy","level":4,"score":0.44100475311279297},{"id":"https://openalex.org/C2778245361","wikidata":"https://www.wikidata.org/wiki/Q409744","display_name":"Calicheamicin","level":3,"score":0.43055835366249084},{"id":"https://openalex.org/C18031839","wikidata":"https://www.wikidata.org/wiki/Q5009796","display_name":"CD20","level":3,"score":0.4273589253425598},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.4198632836341858},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40722590684890747},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3862582743167877},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.37821125984191895},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.36879855394363403},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3474041223526001},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.2031533420085907},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.1380665898323059}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1097/01.hs9.0000843768.58631.ac","doi":"https://doi.org/10.1097/01.hs9.0000843768.58631.ac","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000843768.58631.ac","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:a603603d799c4a4b98b5dd1ee36f80c9","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/a603603d799c4a4b98b5dd1ee36f80c9","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"HemaSphere, Vol 6, Pp 120-121 (2022)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1097/01.hs9.0000843768.58631.ac","doi":"https://doi.org/10.1097/01.hs9.0000843768.58631.ac","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000843768.58631.ac","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3213952290","https://openalex.org/W2988752573","https://openalex.org/W3212076543","https://openalex.org/W2093915554","https://openalex.org/W2890332178","https://openalex.org/W4362697750","https://openalex.org/W2573047674","https://openalex.org/W2988420853","https://openalex.org/W4255424754","https://openalex.org/W2741270568"],"abstract_inverted_index":{"Background:":[0],"CD47":[1,41,58],"is":[2,78,522],"a":[3,79,237,251,320,430,447,469,505],"cell-surface":[4],"ligand":[5],"overexpressed":[6],"in":[7,50,143,160,267,273,284,397,403,417,472,483,512,525],"various":[8],"malignancies":[9],"that":[10,87],"binds":[11,88],"to":[12,17,70,89,93,114,128,295,306,314,356,438,457],"SIRP\u03b1":[13,90],"on":[14,91,184],"effector":[15],"macrophages":[16,92],"promote":[18],"tumor":[19,259],"cell":[20,278],"evasion":[21],"of":[22,25,57,103,120,123,170,192,195,199,212,223,239,248,254,299,322,327,331,391,463],"phagocytosis.":[23],"Blockade":[24],"this":[26,104,476],"CD47\u2013SIRP\u03b1":[27,97],"interaction":[28],"enhances":[29],"phagocytosis":[30],"mediated":[31],"by":[32],"tumor-targeting":[33],"antibodies,":[34],"such":[35],"as":[36,61],"rituximab":[37],"(ritux).":[38],"Agents":[39],"targeting":[40],"combined":[42],"with":[43,146,164,180,246,425,468,514],"ritux":[44,126,181,503],"have":[45],"demonstrated":[46,480,504],"promising":[47,510],"clinical":[48],"activity":[49],"R/R":[51,148,262,518],"NHL;":[52],"however,":[53],"the":[54,96,116,130,141,369,418,526],"broad":[55],"expression":[56],"potentially":[59],"acts":[60],"an":[62],"antigen":[63],"sink,":[64],"reducing":[65],"anti-tumor":[66],"activity,":[67],"and":[68,110,118,127,179,190,197,276,280,311,344,366,377,380,385,401,449,491,509],"leads":[69],"on-target,":[71],"off-tumor":[72],"toxicities,":[73],"including":[74,302],"hemolytic":[75],"anemia.":[76],"CC-95251":[77,124,165,224,341,357,479,501],"novel,":[80],"fully":[81],"human":[82],"immunoglobulin":[83],"G1":[84],"antibody":[85],"(Ab)":[86],"potently":[94],"block":[95],"interaction.":[98],"Aims:":[99],"The":[100,520],"primary":[101],"objectives":[102],"multicenter,":[105],"open-label,":[106],"phase":[107,137],"1,":[108,187],"dose-escalation":[109,477],"dose-expansion":[111,527],"study":[112,521],"were":[113,158,368,412],"evaluate":[115],"safety":[117,507],"tolerability":[119],"escalating":[121],"doses":[122,169,486,496],"+":[125,225,502],"define":[129],"maximum":[131],"tolerated":[132],"dose":[133,139,222,342,358],"(MTD)":[134],"and/or":[135],"recommended":[136],"2":[138,274,404,444,450],"for":[140,373],"combination":[142],"patients":[144],"(pts)":[145],"CD20+":[147,517],"NHL":[149],"(NCT03783403).":[150],"Here,":[151],"we":[152],"report":[153],"interim":[154],"results.":[155],"Methods:":[156],"Pts":[157,234,318],"treated":[159],"28-day":[161],"cycles":[162,326],"(C)":[163],"administered":[166],"intravenously":[167],"at":[168,485,495],"3,":[171],"10,":[172],"or":[173,207,410],"20":[174],"mg/kg":[175,489],"every":[176,200],"week":[177],"(QW)":[178],"375":[182],"mg/m2":[183],"days":[185],"(D)":[186],"8,":[188],"15,":[189],"22":[191],"C1,":[193],"D1":[194,198],"C2\u20135,":[196],"other":[201],"cycle":[202],"C6\u201324":[203],"until":[204],"disease":[205,293],"progression":[206],"unacceptable":[208],"toxicity.":[209],"Results:":[210],"As":[211],"5":[213],"August":[214],"2021,":[215],"17":[216],"pts":[217,249,291,347,399,405,428,436,445,451,513],"had":[218,235,292,452],"received":[219,236,319],"\u2265":[220,349,382,393,497],"1":[221,285,340,350,473],"ritux.":[226],"Median":[227,329,455],"age":[228],"was":[229,333,339,422,459],"67":[230],"(range":[231,241,324,335],"30\u201384)":[232],"years.":[233],"median":[238,321],"3":[240,383,394,488,498],"1\u20137)":[242],"prior":[243,252,297,440],"systemic":[244],"therapies,":[245],"100%":[247],"having":[250],"history":[253],"anti-CD20":[255,308,441],"Ab":[256],"exposure.":[257],"Enrolled":[258],"types":[260],"included":[261,395],"diffuse":[263],"large":[264],"B-cell":[265],"lymphoma":[266,272,279,283],"13":[268],"(77%)":[269],"pts,":[270],"follicular":[271],"(12%),":[275],"mantle":[277],"marginal":[281],"zone":[282],"(6%)":[286],"pt":[287],"each.":[288],"Twelve":[289],"(71%)":[290],"refractory":[294,305,437],"any":[296,307,374,439],"line":[298],"therapy":[300],"(LOT),":[301],"10":[303],"(59%)":[304],"Ab-containing":[309,442],"regimen,":[310,443],"9":[312,398,435],"(53%)":[313,400],"their":[315],"last":[316],"LOT.":[317],"4":[323,426],"1\u201314)":[325],"CC-95251.":[328],"duration":[330],"treatment":[332],"16.4":[334],"2.1\u201353.1)":[336],"weeks.":[337,461],"There":[338],"reduction,":[343],"6":[345],"(35%)":[346],"experienced":[348],"treatment-emergent":[351],"adverse":[352,389],"event":[353],"(TEAE)":[354],"leading":[355],"interruption.":[359],"MTD":[360],"has":[361],"not":[362],"been":[363],"reached.":[364],"Neutropenia":[365],"infection":[367,402],"most":[370],"common":[371],"TEAEs":[372],"grade":[375,381,392],"(71%":[376],"59%":[378],"respectively)":[379],"(59%":[384],"29%":[386],"respectively).":[387],"Treatment-related":[388],"events":[390],"neutropenia":[396],"(12%);":[406],"no":[407],"treatment-related":[408],"anemia":[409],"deaths":[411],"reported.":[413],"Overall":[414],"response":[415,432,458,464],"rate":[416],"efficacy":[419,511],"evaluable":[420],"population":[421],"56%":[423],"(9/16),":[424],"(25%)":[427],"achieving":[429],"complete":[431],"(CR).":[433],"Of":[434],"achieved":[446],"CR":[448,470],"stable":[453],"disease.":[454],"time":[456],"7.9":[460],"Duration":[462],"ranged":[465],"7.4\u201328.1":[466],"weeks":[467],"ongoing":[471],"pt.":[474],"In":[475],"study,":[478],"dose-proportional":[481],"increases":[482],"exposure":[484],">":[487],"QW":[490],"full":[492],"receptor":[493],"occupancy":[494],"mg/kg.":[499],"Summary/Conclusion:":[500],"manageable":[506],"profile":[508],"heavily":[515],"pretreated":[516],"NHL.":[519],"currently":[523],"enrolling":[524],"phase.":[528]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-06-24T00:00:00"}